Centessa Pharmaceuticals plc ADR [NASDAQ: CNTA] closed the trading session at $22.52 on 2025-11-05. The day’s price range saw the stock hit a low of $17.05, while the highest price level was $22.885.
The stocks have a year to date performance of 43.71 percent and weekly performance of -6.09 percent. The stock has been moved at 85.96 percent over the last six months. The stock has performed -2.60 percent around the most recent 30 days and changed 31.08 percent over the most recent 3-months.
If compared to the average trading volume of 1.13M shares, CNTA reached to a volume of 10088264 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Centessa Pharmaceuticals plc ADR [CNTA]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for CNTA shares is $33.23 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on CNTA stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Stephens have made an estimate for Centessa Pharmaceuticals plc ADR shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on October 28, 2025. While these analysts kept the previous recommendation, Wells Fargo raised their target price to Overweight. The new note on the price target was released on September 03, 2025, representing the official price target for Centessa Pharmaceuticals plc ADR stock. Previously, the target price had yet another raise to $40, while Oppenheimer analysts kept a Outperform rating on CNTA stock.
The Price to Book ratio for the last quarter was 8.74, with the Price to Cash per share for the same quarter was set at 1.87.
CNTA stock trade performance evaluation
Centessa Pharmaceuticals plc ADR [CNTA] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -6.09. With this latest performance, CNTA shares dropped by -2.60% in over the last four-week period, additionally plugging by 85.96% over the last 6 months – not to mention a rise of 34.45% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CNTA stock in for the last two-week period is set at 45.10, with the RSI for the last a single of trading hit 1.76, and the three-weeks RSI is set at 1.35 for Centessa Pharmaceuticals plc ADR [CNTA]. The present Moving Average for the last 50 days of trading for this stock 22.06, while it was recorded at 23.89 for the last single week of trading, and 16.59 for the last 200 days.
Centessa Pharmaceuticals plc ADR [CNTA]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Centessa Pharmaceuticals plc ADR [CNTA] shares currently have an operating margin of -1374.49% and a Gross Margin at 93.94%. Centessa Pharmaceuticals plc ADR’s Net Margin is presently recorded at -1530.61%.
Centessa Pharmaceuticals plc ADR (CNTA) Capital Structure & Debt Analysis
According to recent financial data for Centessa Pharmaceuticals plc ADR. ( CNTA), the Return on Equity (ROE) stands at -72.95%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -51.74%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Centessa Pharmaceuticals plc ADR’s Return on Invested Capital (ROIC) is -49.84%, showcasing its effectiveness in deploying capital for earnings.
Centessa Pharmaceuticals plc ADR (CNTA) Efficiency & Liquidity Metrics
Based on Centessa Pharmaceuticals plc ADR’s (CNTA) latest financial statements, the Debt-to-Equity Ratio is 0.34%, indicating its reliance on debt financing relative to shareholder equity.
Centessa Pharmaceuticals plc ADR (CNTA) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Centessa Pharmaceuticals plc ADR. (CNTA) effectively leverages its workforce, generating an average of -$2993116.88 per employee. The company’s liquidity position is robust, with a Current Ratio of 10.12% and a Quick Ratio of 10.12%, indicating strong ability to cover short-term liabilities.
Earnings per share (EPS) analysis for Centessa Pharmaceuticals plc ADR [CNTA] stock
With the latest financial reports released by the company, Centessa Pharmaceuticals plc ADR posted -0.37/share EPS, while the average EPS was predicted by analysts to be reported at -0.39/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 0.02. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for CNTA. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Centessa Pharmaceuticals plc ADR go to 4.81%.
Centessa Pharmaceuticals plc ADR [CNTA]: Institutional Ownership
There are presently around $94.72%, or 95.18%% of CNTA stock, in the hands of institutional investors. The top three institutional holders of CNTA stocks are: MEDICXI VENTURES MANAGEMENT (JERSEY) LTD with ownership of 19.96 million shares, which is approximately 18.233%. GENERAL ATLANTIC, L.P., holding 9.68 million shares of the stock with an approximate value of $$87.43 million in CNTA stocks shares; and GENERAL ATLANTIC, L.P., currently with $$51.6 million in CNTA stock with ownership which is approximately 5.2191%.
